Innate Pharma Cash Flow Quality Index
Innate Pharma cash flow quality index. Innate Pharma (IPHA) has a Cash Flow Quality Index of -6.67x as of June 2023. Operating cash flow of $-11.46 Million is below net income of $1.72 Million, suggesting accrual-heavy earnings not yet converted to cash. See IPHA free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Innate Pharma (2016–2018)
Cash flow quality index of Innate Pharma from 2016 to 2018. Historical Cash Flow Quality Index for Innate Pharma across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore IPHA cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Innate Pharma Cash Flow Quality Index by Year (2016–2018)
Innate Pharma cash flow quality index by year from 2016 to 2018. Year-by-year earnings quality comparison for Innate Pharma. For the full cash flow conversion analysis, see Innate Pharma (IPHA) cash flow conversion.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2018 | -10.67x | $-32.53 Million | $3.05 Million | ▼ -266.0% |
| 2016 | -2.92x | $-36.85 Million | $12.64 Million | — |